David Derse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
David Derse has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Shawn A. Hill
HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702-1201
5 shared publicationsGerald Princler
HIV Drug Resistance Program, National Cancer Institute-Frederick, P.O. Box B, Frederick, Maryland 21702-1201,1 Basic Research Program, SAIC-Frederick, Inc,2 HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland 20892,3 Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan4
4 shared publicationsGisela Heidecker
HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702-1201
4 shared publicationsPatricia A. Lloyd
Basic Research Program SAIC-Frederick 21702 Frederick Maryland
3 shared publicationsPatricia Lloyd
HIV Drug Resistance Program, National Cancer Institute-Frederick, P.O. Box B, Frederick, Maryland 21702-1201,1 Basic Research Program, SAIC-Frederick, Inc,2 HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland 20892,3 Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan4
3 shared publicationsGerald L Princler
Basic Research Laboratory, National Cancer Institute, Frederick, MD 21702-1201, USA
2 shared publications
Latest Publications
- 1 May 2007
- Published by American Society for Microbiology in Journal of Virology
- Vol. 81 (9) , 4422-4428
Phenotypic and Genotypic Comparisons of Human T-Cell Leukemia Virus Type 1 Reverse Transcriptases from Infected T-Cell Lines and Patient Samples
It is well established that cell-free infection with human T-cell leukemia virus type 1 (HTLV-1) is less efficient than that with other retroviruses, though the specific infectivities of only a limited number of HTLV-1 isolates have been quantified. Earlier work indicated that a postentry step in the infectious cycle accounted for the poor cell-free infectivity of HTLV-1. To determine whether variations in the pol gene sequence correlated with virus infectivity, we sequenced and phenotypically tested pol genes from a variety of HTLV-1 isolates derived from primary sources, transformed cell lines, and molecular clones. The pol genes and deduced amino acid sequences from 23 proviruses were sequenced and compared with 14 previously published sequences, revealing a limited number of amino acid variations among isolates. The variations appeared to be randomly dispersed among primary isolates and proviruses from cell lines and molecular clones. In addition, there was no correlation between reverse transcriptase sequence and the disease phenotype of the original source of the virus isolate. HTLV-1 pol gene fragments encoding reverse transcriptase were amplified from a variety of isolates and were subcloned into HTLV-1 vectors for both single-cycle infection and spreading-infection assays. Vectors carrying pol genes that matched the consensus sequence had the highest titers, and those with the largest number of variations from the consensus had the lowest titers. The molecular clone from CS-1 cells had four amino acid differences from the consensus sequence and yielded infectious titers that were approximately eight times lower than those of vectors encoding a consensus reverse transcriptase.
- 1 May 2007
- Published by American Society for Microbiology in Journal of Virology
- Vol. 81 (9) , 4422-4428
Phenotypic and Genotypic Comparisons of Human T-Cell Leukemia Virus Type 1 Reverse Transcriptases from Infected T-Cell Lines and Patient Samples
It is well established that cell-free infection with human T-cell leukemia virus type 1 (HTLV-1) is less efficient than that with other retroviruses, though the specific infectivities of only a limited number of HTLV-1 isolates have been quantified. Earlier work indicated that a postentry step in the infectious cycle accounted for the poor cell-free infectivity of HTLV-1. To determine whether variations in the pol gene sequence correlated with virus infectivity, we sequenced and phenotypically tested pol genes from a variety of HTLV-1 isolates derived from primary sources, transformed cell lines, and molecular clones. The pol genes and deduced amino acid sequences from 23 proviruses were sequenced and compared with 14 previously published sequences, revealing a limited number of amino acid variations among isolates. The variations appeared to be randomly dispersed among primary isolates and proviruses from cell lines and molecular clones. In addition, there was no correlation between reverse transcriptase sequence and the disease phenotype of the original source of the virus isolate. HTLV-1 pol gene fragments encoding reverse transcriptase were amplified from a variety of isolates and were subcloned into HTLV-1 vectors for both single-cycle infection and spreading-infection assays. Vectors carrying pol genes that matched the consensus sequence had the highest titers, and those with the largest number of variations from the consensus had the lowest titers. The molecular clone from CS-1 cells had four amino acid differences from the consensus sequence and yielded infectious titers that were approximately eight times lower than those of vectors encoding a consensus reverse transcriptase.
- 20 February 2007
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (8) , 2915-2920
Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid
Human T cell leukemia virus type 1 (HTLV-1) has evolved a remarkable strategy to thwart the antiviral effects of the cellular cytidine deaminase APOBEC3G (hA3G). HTLV-1 infects T lymphocytes in vivo, where, like HIV-1, it is likely to encounter hA3G. HIV-1 counteracts the innate antiviral activity of hA3G by producing an accessory protein, Vif, which hastens the degradation of hA3G. In contrast, HTLV-1 does not encode a Vif homologue; instead, HTLV-1 has evolved a cis-acting mechanism to prevent hA3G restriction. We demonstrate here that a peptide motif in the C terminus of the HTLV-1 nucleocapsid (NC) domain inhibits hA3G packaging into nascent virions. Mutation of amino acids within this region resulted in increased levels of hA3G incorporation into virions and increased susceptibility to hA3G restriction. Elements within the C-terminal extension of the NC domain are highly conserved among the primate T cell leukemia viruses, but this extension is absent in all other retroviral NC proteins.
- 20 February 2007
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (8) , 2915-2920
Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid
Human T cell leukemia virus type 1 (HTLV-1) has evolved a remarkable strategy to thwart the antiviral effects of the cellular cytidine deaminase APOBEC3G (hA3G). HTLV-1 infects T lymphocytes in vivo, where, like HIV-1, it is likely to encounter hA3G. HIV-1 counteracts the innate antiviral activity of hA3G by producing an accessory protein, Vif, which hastens the degradation of hA3G. In contrast, HTLV-1 does not encode a Vif homologue; instead, HTLV-1 has evolved a cis-acting mechanism to prevent hA3G restriction. We demonstrate here that a peptide motif in the C terminus of the HTLV-1 nucleocapsid (NC) domain inhibits hA3G packaging into nascent virions. Mutation of amino acids within this region resulted in increased levels of hA3G incorporation into virions and increased susceptibility to hA3G restriction. Elements within the C-terminal extension of the NC domain are highly conserved among the primate T cell leukemia viruses, but this extension is absent in all other retroviral NC proteins.
- Open Access
- 1 February 2006
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 281 (7) , 3964-3971
Synthesis, Processing, and Composition of the Virion-associated HTLV-1 Reverse Transcriptase
- 1 February 2006
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 281 (7) , 3964-3971
Open AccessSynthesis, Processing, and Composition of the Virion-associated HTLV-1 Reverse Transcriptase
- 1 January 2004
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 9 (1-3) , 2495-9
Infectious transmission and replication of human T-cell leukemia virus type 1
Retrovirus infection proceeds by attachment of the envelope glycoprotein to a cell surface receptor, followed by fusion of the viral and cellular membranes. Once in the cell, the viral enzymes and structural proteins form a replication complex that converts the single-stranded viral genomic RNA into a double-stranded DNA, which is then integrated into the host cell chromosome. For HTLV-1, these events are not well characterized. We have developed cell culture systems, infectious molecular clones, and viral vectors that can be used to characterize the mechanisms of HTLV-1 infection and replication. Infection with cell-free HTLV-1 virions is orders of magnitude less efficient compared with other retroviruses. This inefficiency is the result of a block in the replication process after the virion is bound to the cell surface. We are determining whether this block is conferred by the viral replication enzymes, results from the actions of cellular restriction factors, reflects the need for cell-cell contact, or is caused by a combination of these factors.
- 1 January 2004
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 9 (1-3) , 2495-9
Infectious transmission and replication of human T-cell leukemia virus type 1
Retrovirus infection proceeds by attachment of the envelope glycoprotein to a cell surface receptor, followed by fusion of the viral and cellular membranes. Once in the cell, the viral enzymes and structural proteins form a replication complex that converts the single-stranded viral genomic RNA into a double-stranded DNA, which is then integrated into the host cell chromosome. For HTLV-1, these events are not well characterized. We have developed cell culture systems, infectious molecular clones, and viral vectors that can be used to characterize the mechanisms of HTLV-1 infection and replication. Infection with cell-free HTLV-1 virions is orders of magnitude less efficient compared with other retroviruses. This inefficiency is the result of a block in the replication process after the virion is bound to the cell surface. We are determining whether this block is conferred by the viral replication enzymes, results from the actions of cellular restriction factors, reflects the need for cell-cell contact, or is caused by a combination of these factors.
- Open Access
- 1 August 2003
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 188 (3) , 424-427
Susceptibility of Human T Cell Leukemia Virus Type I to Nucleoside Reverse Transcriptase Inhibitors
A single-cycle infection assay with recombinant viral vectors was developed to study human T cell leukemia virus type I (HTLV-I) replication and its
- 1 August 2003
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 188 (3) , 424-427
Open AccessSusceptibility of Human T Cell Leukemia Virus Type I to Nucleoside Reverse Transcriptase Inhibitors
A single-cycle infection assay with recombinant viral vectors was developed to study human T cell leukemia virus type I (HTLV-I) replication and its
- 28 March 2003
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 299 (5615) , 2002-2003
Seeing Is Believing
- 28 March 2003
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 299 (5615) , 2002-2003
Seeing Is Believing
- 14 March 2003
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 299 (5613) , 1670-1671
Forced Entry--or Does HTLV-I Have the Key?
How do retroviruses pass from an infected host cell to a new uninfected target cell? In a Perspective, [Derse and Heidecker][1] suggest an answer. According to new work, a virological synapse-analogous to the immunological synapse between immune cells-forms between T cells infected with HTLV-1 and uninfected T cells ([ Igakura et al. ][2]). Viral particles accumulate within the tight intercellular space of the virological synapse, which facilitates their passage into uninfected T cells. [1]: http://www.sciencemag.org/cgi/content/full/299/5613/1670 [2]: http://www.sciencemag.org/cgi/content/short/299/5613/1713
- 14 March 2003
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 299 (5613) , 1670-1671
Forced Entry--or Does HTLV-I Have the Key?
How do retroviruses pass from an infected host cell to a new uninfected target cell? In a Perspective, [Derse and Heidecker][1] suggest an answer. According to new work, a virological synapse-analogous to the immunological synapse between immune cells-forms between T cells infected with HTLV-1 and uninfected T cells ([ Igakura et al. ][2]). Viral particles accumulate within the tight intercellular space of the virological synapse, which facilitates their passage into uninfected T cells. [1]: http://www.sciencemag.org/cgi/content/full/299/5613/1670 [2]: http://www.sciencemag.org/cgi/content/short/299/5613/1713
- 15 September 2001
- Published by American Society for Microbiology in Journal of Virology
- Vol. 75 (18) , 8461-8468
Examining Human T-Lymphotropic Virus Type 1 Infection and Replication by Cell-Free Infection with Recombinant Virus Vectors
A sensitive and quantitative cell-free infection assay, utilizing recombinant human T-cell leukemia virus type 1 (HTLV-1)-based vectors, was developed in order to analyze early events in the virus replication cycle. Previous difficulties with the low infectivity and restricted expression of the virus have prevented a clear understanding of these events. Virus stocks were generated by transfecting cells with three plasmids: (i) a packaging plasmid encoding HTLV-1 structural and regulatory proteins, (ii) an HTLV-1 transfer vector containing either firefly luciferase or enhanced yellow fluorescent protein genes, and (iii) an envelope expression plasmid. Single-round infections were initiated by exposing target cells to filtered supernatants and quantified by assaying for luciferase activity in cell extracts or by enumerating transduced cells by flow cytometry. Transduction was dependent on reverse transcription and integration of the recombinant virus genome, as shown by the effects of the reverse transcriptase inhibitor 3′-azido-3′-deoxythymidine (AZT) and by mutation of the integrase gene in the packaging vector, respectively. The 50% inhibitory concentration of AZT was determined to be 30 nM in this HTLV-1 replication system. The stability of HTLV-1 particles, pseudotyped with either vesicular stomatitis virus G protein or HTLV-1 envelope, was typical of retroviruses, exhibiting a half-life of approximately 3.5 h at 37°C. The specific infectivity of recombinant HTLV-1 virions was at least 3 orders of magnitude lower than that of analogous HIV-1 particles, though both were pseudotyped with the same envelope. Thus, the low infectivity of HTLV-1 is determined in large part by properties of the core particle and by the efficiency of postentry processes.
- 15 September 2001
- Published by American Society for Microbiology in Journal of Virology
- Vol. 75 (18) , 8461-8468
Examining Human T-Lymphotropic Virus Type 1 Infection and Replication by Cell-Free Infection with Recombinant Virus Vectors
A sensitive and quantitative cell-free infection assay, utilizing recombinant human T-cell leukemia virus type 1 (HTLV-1)-based vectors, was developed in order to analyze early events in the virus replication cycle. Previous difficulties with the low infectivity and restricted expression of the virus have prevented a clear understanding of these events. Virus stocks were generated by transfecting cells with three plasmids: (i) a packaging plasmid encoding HTLV-1 structural and regulatory proteins, (ii) an HTLV-1 transfer vector containing either firefly luciferase or enhanced yellow fluorescent protein genes, and (iii) an envelope expression plasmid. Single-round infections were initiated by exposing target cells to filtered supernatants and quantified by assaying for luciferase activity in cell extracts or by enumerating transduced cells by flow cytometry. Transduction was dependent on reverse transcription and integration of the recombinant virus genome, as shown by the effects of the reverse transcriptase inhibitor 3′-azido-3′-deoxythymidine (AZT) and by mutation of the integrase gene in the packaging vector, respectively. The 50% inhibitory concentration of AZT was determined to be 30 nM in this HTLV-1 replication system. The stability of HTLV-1 particles, pseudotyped with either vesicular stomatitis virus G protein or HTLV-1 envelope, was typical of retroviruses, exhibiting a half-life of approximately 3.5 h at 37°C. The specific infectivity of recombinant HTLV-1 virions was at least 3 orders of magnitude lower than that of analogous HIV-1 particles, though both were pseudotyped with the same envelope. Thus, the low infectivity of HTLV-1 is determined in large part by properties of the core particle and by the efficiency of postentry processes.